Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01193
|
|||||
| Drug Name |
Prasterone
|
|||||
| Synonyms |
17-Chetovis; 17-Hormoforin; 3beta-hydroxyandrost-5-en-17-one; 5,6-Dehydroisoandrosterone; 5,6-Dehydroisoandrostorone; 5,6-Didehydroisoandrosterone; 5-Dehydroepiandrosterone; 53-43-0; Andrestenol; Androstenolone; Caswell No 051F; DHEA; Dehydro-epi-androsterone; Dehydroepiandrosterone; Dehydroisoandrosterone; Diandron; Diandrone; Epiandrosterone, 5-dehydro-; Intrarosa; PRASTERONE; Prasterona; Prasteronum; Prestara; Psicosterone; Siscelar plus; trans-Dehydroandrosterone
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Hypercalcemia [ICD11:5B91.0] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C19H28O2
|
|||||
| Canonical SMILES |
CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(C4)O)C
|
|||||
| InChI |
InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3/t13-,14-,15-,16-,18-,19-/m0/s1
|
|||||
| InChIKey |
FMGSKLZLMKYGDP-USOAJAOKSA-N
|
|||||
| CAS Number |
CAS 53-43-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 288.4 | Topological Polar Surface Area | 37.3 | ||
| Heavy Atom Count | 21 | Rotatable Bond Count | 0 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 2 | |||
| XLogP |
3.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103302695
,104095449
,11446567
,12014907
,12146065
,14751238
,14775640
,17404931
,1983
,24278369
,24702275
,26703947
,29224908
,3135651
,4449
,46387028
,46508824
,47193749
,47959958
,48413520
,48415849
,49681751
,49747225
,49857278
,50172721
,53777474
,53788218
,56312069
,56312916
,56313484
,56313819
,56320669
,56320670
,57323014
,596018
,75250
,7885884
,8145544
,8153636
,837865
,841442
,87566797
,91692812
,92297484
,92303742
,92308678
,92309040
,92709895
,93167098
,96025095
|
|||||
| ChEBI ID |
ChEBI:28689
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| MRP4 | Transporter Info | Multidrug resistance-associated protein 4 | Substrate | [3] | ||
| MRP8 | Transporter Info | Multidrug resistance-associated protein 8 | Substrate | [4] | ||
| OAT3 | Transporter Info | Organic anion transporter 3 | Substrate | [5] | ||
| References | ||||||
| 1 | Prasterone was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
| 3 | Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003 Apr 15;371(Pt 2):361-7. | |||||
| 4 | Human multidrug resistance protein 8 (MRP8/ABCC11), an apical efflux pump for steroid sulfates, is an axonal protein of the CNS and peripheral nervous system. Neuroscience. 2006;137(4):1247-57. | |||||
| 5 | Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.